322. TMVR for the Treatment of Mitral Regurgitation: A State-of-the-Art Review.
作者: Francesco Tartaglia.;Giulia Antonelli.;Mauro Gitto.;Kamil Stankowski.;Dario Donia.;Giulio Stefanini.;Azeem Latib.;Antonio Colombo.;Antonio Mangieri.;Mauro Chiarito.
来源: Circ Cardiovasc Interv. 2025年18卷10期e015298页
Mitral regurgitation is the most common valve disease worldwide. Despite its wide success in inoperable or high-risk surgical patients, transcatheter edge-to-edge repair remains limited by some anatomic features and the non-negligible rate of significant residual regurgitation. Transcatheter mitral valve replacement has emerged as a viable alternative that promises to overcome these issues, but its development has been progressing slowly. This review aims to provide a comprehensive overview of the current state of transcatheter mitral valve replacement, including patient selection, procedural techniques, and currently available outcomes.
323. Acute Lesion Visualization Following Interventional CMR Flutter Ablation Using PATRIOT CMR Imaging.
作者: Luuk H G A Hopman.;Nikki van Pouderoijen.;Michiel J B Kemme.;Raschel van Luijk.;Pranav Bhagirath.;Cornelis Allaart.;Marco J W Gotte.
来源: Circ Cardiovasc Imaging. 2025年e018540页 327. Letter by Ji and Zhang Regarding Article, "Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial)".328. Letter by He et al Regarding Article, "Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial)".330. Letter by Liu et al Regarding Article, "Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial)".331. Letter by Santini and Pola Regarding Article, "Rivaroxaban for 18 Months versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial)".333. Adipose Tissue in and Around the Heart: Structural and Functional Insights From Cardiac Magnetic Resonance.
作者: Andrea Barison.;Giovanni Donato Aquaro.;Santo Dellegrottaglie.;Stefania Rizzo.;Antonio De Luca.;Viviana Maestrini.;Alessandra Scatteia.;Andrea Baggiano.;Monica De Gaspari.;Pasquale Perrone Filardi.;Gianfranco Sinagra.;Massimo Imazio.;Cristina Basso.;Martina Perazzolo Marra.; .
来源: Circulation. 2025年152卷10期717-733页
Cardiac adipose tissue is normally present in the epicardium, but a variable amount can also be present in the myocardium, particularly in the subepicardial regions of the right ventricular anterolateral and apical regions. Pathological adipose tissue changes may occur in both ischemic (previous myocardial infarction) and nonischemic (previous myocarditis, arrhythmogenic cardiomyopathy, lipomatous hypertrophy of the interatrial septum, cardiac lipomas and liposarcomas) conditions, with or without extensive replacement-type myocardial fibrosis. Cardiac magnetic resonance is the gold standard imaging technique to characterize myocardial tissue changes and to distinguish between physiological and pathological cardiac fat deposits. In this review, we present the most common conditions presenting with myocardial fatty infiltration or with fatty replacement and the best magnetic resonance sequences to detect them, providing a comparison with histological findings and discussing their clinical significance.
334. Response by Yamashita et al to Letter Regarding Article, "Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial)".335. Patient and Physician Perspectives on Cardiovascular Risk: A Multicenter Survey of Communication Gaps Among Hospitalized Patients in Spain.
作者: Juan Górriz-Magaña.;Ramon Maruri-Sánchez.;Ane Elorriaga.;Nahikari Salterain-González.;Alicia Prieto-Lobato.;Raúl Gascueña Rubia.;Isabel Monedero Sánchez.;Ana Elvira-Laffond.;Miguel Lapena Reguero.;Amanda Leandro Barros.;Cristina Villabona Rivas.;Alejandro Gutiérrez-Fernández.;César Jiménez-Méndez.;Silvia Prieto-González.;María Melendo-Viu.;Blanca Alcón Durán.;Emilio Blanco López.;Clara Bonanad Lozano.;Alejandro Durante-López.;Anna Carrasquer.;Pedro Martínez-Losas.;Teresa Alvarado Casas.;Pedro Pájaro Merino.;Victor Juárez-Olmos.;Javier Lopez-Pais.;Michelle M Kittleson.;Pablo Díez-Villanueva.;Jordi Bañeras.
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷10期e011837页
Effective risk communication is essential in managing cardiovascular disease, the leading cause of global mortality. Clear communication between patients and physicians supports informed decision-making, yet comprehension gaps persist. We aimed to assess the quality of risk communication during hospital admissions for cardiovascular events, from patient and physician perspectives, and identify discrepancies in risk perception and associated factors.
336. Accelerometer-Measured Physical Activity After Mitral Valve Surgery: An Analysis of the UK Mini Mitral Randomized Controlled Trial.
作者: Janelle M Wagnild.;Christopher Bayliss.;Rebecca H Maier.;Emmanuel Ogundimu.;Joseph Zacharias.;Enoch F Akowuah.
来源: Circulation. 2025年152卷17期1234-1245页
Wearable accelerometer devices measure free-living physical activity and sleep without relying on self-reports. Their utility to measure and compare recovery of physical function after cardiac surgery procedures has not been previously studied in the setting of a randomized controlled trial.
337. Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial.
作者: Joseph Campain.;Catharine Griskowitz.;Chloe Newlands.;Brian L Claggett.;Ian J Kulac.;Shaina McGinnis.;Ilya Giverts.;Fabely Moreno.;Alexandra Minasian.;Cheshta Prasad.;Lillian Rupert.;Isabela Landsteiner.;Nick Iskenderian.;Caroline J Coats.;Matthew M Y Lee.;Martin S Maron.;Anjali T Owens.;Daniel L Jacoby.;Stephen B Heitner.;Stuart Kupfer.;Fady I Malik.;Amy Wohltman.;Rajeev Malhotra.;Gregory D Lewis.
来源: Circulation. 2025年152卷14期990-1002页
Post-exercise oxygen uptake recovery (VO2Rec) is slow in advanced heart failure. We sought to establish easily derived VO2Rec measures and evaluate their cardiospecificity and prognostic relevance in patients with dyspnea on exertion. We further sought to determine VO2Rec modifiability proportional to changes in cardiac function with disease-specific treatment of obstructive hypertrophic cardiomyopathy.
338. Health Status Outcomes With Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting in ISCHEMIA.
作者: Chetan P Huded.;John A Spertus.;Philip G Jones.;Sean M O'Brien.;Daniel B Mark.;Sripal Bangalore.;Gregg W Stone.;David O Williams.;Harvey D White.;William E Boden.;Harmony R Reynolds.;Judith S Hochman.;David J Maron.; .
来源: Circulation. 2025年152卷12期846-858页
In ISCHEMIA (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches), an invasive strategy demonstrated better health status outcomes than a conservative strategy in patients with chronic coronary disease (CCD). Some previous studies have shown greater health status benefits with coronary artery bypass grafting (CABG) than percutaneous coronary intervention (PCI). Whether the health status benefits of invasive management in ISCHEMIA were driven primarily by participants treated with CABG is unknown.
339. Network Meta-Analysis of Quality of Life in Heart Failure With Reduced Ejection Fraction.
作者: Robert Margaryan.;Nariman Sepehrvand.;Wouter Ouwerkerk.;Jasper Tromp.;Ricky D Turgeon.;Justin A Ezekowitz.
来源: Circ Heart Fail. 2025年e013074页
Although the effects of various combinations of treatments on mortality and morbidity outcomes in heart failure with reduced ejection fraction (HFrEF) have been evaluated, the impact on quality of life is unknown. This study evaluated and compared the composite impact of pharmacological therapies on quality of life in HFrEF using a frequentist network meta-analysis and systematic review methodology.
340. Microvascular Function and Ambulatory Capacity in Peripheral Artery Disease.
作者: Alexander E Sullivan.;Adam Behroozian.;Crystal Coolbaugh.;Emily Shardelow.;Emily K Smith.;Quinn S Wells.;Daniel G Clair.;Aaron W Aday.;C Louis Garrard.;John A Curci.;Tara A Holder.;Joey V Barnett.;Matthew S Freiberg.;Rachelle L Crescenzi.;Denis J Wakeham.;Christopher M Hearon.;Manus J Donahue.;Joshua A Beckman.
来源: Circ Cardiovasc Interv. 2025年18卷10期e015582页
Patients with peripheral artery disease experience walking impairment that is incompletely explained by large-artery atherosclerotic occlusive disease and abnormal ankle-brachial index (ABI). Microvascular dysfunction is associated with adverse outcomes, including amputation, but its effect on ambulation is unknown. We tested the hypothesis that skeletal muscle microvascular function directly associates with walking distance, is a more sensitive indicator of walking distance than conduit artery blood inflow, and correlates with ambulatory improvement following peripheral artery disease interventions.
|